However, compared with recovered COVID-19 patients without cancer, IFITM2 was downregulated in COVID-19 patients with hematologic cancer (exitus) (Figure 10K). This evidence concerns the gene IFITM2 and hematopoietic and lymphoid cell neoplasm.